A pragmatic approach to sample acceptance and rejection

被引:16
作者
Cadamuro, Janne [1 ]
Simundic, Ana-Maria [2 ]
Ajzner, Eva [3 ]
Sandberg, Sverre [4 ,5 ,6 ]
机构
[1] Paracelsus Med Univ, Dept Lab Med, Salzburg, Austria
[2] Univ Hosp Sveti Duh, Dept Med Lab Diagnost, Zagreb, Croatia
[3] Josa Andras Univ Hosp, Cent Lab, Nyiregyhaza, Hungary
[4] Haraldsplass Deaconess Hosp, Norwegian Qual Improvement Lab Examinat Noklus, Bergen, Norway
[5] Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway
[6] Haukeland Hosp, Lab Clin Biochem, Bergen, Norway
关键词
Postanalytics; Preanalytics; Hemolysis; Patient safety; LABORATORIES; MANAGEMENT; HEMOLYSIS; QUALITY;
D O I
10.1016/j.clinbiochem.2017.02.001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Sample rejection due to preanalytical errors is very common in many medical laboratories worldwide, though the decision when and how to refrain from analyzing such samples is handled very heterogeneously. As a rational, it is mostly stated that it is done to prevent the patient from being harmed by wrong medical decisions based on such values. But when thinking of the consequences of laboratory results instead of their quality being important per se, the rejection of preanalytically altered samples might be harming the patient by the need of re-collection and timely delay. The importance of the result is never the result in itself, but the consequences the result will have for the treatment or monitoring of the patient. Then again, these consequences are only foreseeable if the specific clinical situation or the general clinical setting for the respective parameter is known. Based on this mindset it can be necessary to modify general performance specifications into "personalized" performance specifications for each laboratory parameter, which can only be achieved in close interaction with clinicians. In this opinion paper we want to present a pragmatic approach to the development of such performance specifications by extending the recommendations of the 1st Strategic Conference of the EFLM on 'Defining analytical performance goals 15 years after the Stockholm Conference on Quality Specifications in Laboratory Medicine', depending on the availability of clinical information, data on biological variation or state-of-the-art recommendations, thereby redirecting laboratory medicine to a more patient focussed profession. (C) 2017 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:579 / 581
页数:3
相关论文
共 19 条
  • [1] [Anonymous], 2012, MED LAB REQ QUAL COM
  • [2] Badrick T, 2016, CLIN BIOCHEM REV, V37, P139, DOI DOI 10.1515/CCLM-2017-1104
  • [3] Burghuber D. C., 1990, CANCER, V65, P1386
  • [4] Clinical and Laboratory Standards Institute, 2012, HEM ICT LIP TURB IND
  • [5] Clinical Laboratory Standards Institute, 2008, Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays
  • [6] Approved Guideline
  • [7] EFLM, PREAN PHAS
  • [8] Clinical Laboratory Quality Practices When Hemolysis Occurs
    Howanitz, Peter J.
    Lehman, Christopher M.
    Jones, Bruce A.
    Meier, Frederick A.
    Horowitz, Gary L.
    [J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2015, 139 (07) : 901 - 906
  • [9] International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) - Working Group Laboratory Errors and Patient Safety (WG-LEPS), WORK GROUP LAB ERR P
  • [10] Recommendations for detection and management of unsuitable samples in clinical laboratories
    Lippi, Giuseppe
    Banfi, Giuseppe
    Buttarello, Mauro
    Ceriotti, Ferruccio
    Daves, Massimo
    Dolci, Alberto
    Caputo, Marco
    Giavarina, Davide
    Montagnana, Martina
    Micon, Valentino
    Milanesi, Bruno
    Mosca, Andrea
    Morandini, Margherita
    Luca, Gian
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2007, 45 (06) : 728 - 736